Transient Treg depletion enhances therapeutic anti-cancer vaccination
Scott A. Fisher, Wayne J. Aston, Jonathan Chee, Andrea Khong, Amanda L. Cleaver, Jessica N. Solin, Shaokang Ma, W. Joost Lesterhuis, Ian Dick, Robert A. Holt, Jenette Creaney, Louis Boon, Bruce Robinson and Richard A. Lake
Version of Record online: 21 NOV 2016 | DOI: 10.1002/iid3.136
Regulatory T cells (Treg) play an important role in suppressing anti- immunity. Given the recent advances in the use of immune based cancer therapies, the role of Treg suppression in limiting anti- immunity is currently generating great interest. In this work, we show that the BALB/c FoxP3.dtr transgenic mouse is an ideal model to explore the full therapeutic potential of Treg depletion. We show that DTX-mediated Treg depletion is transient and dose-dependent; it can lead to strong anti-tumor immunity and complete tumor regression of several different solid tumors. Importantly, we show that partial Treg depletion improves the efficacy of tumor specific vaccine immunotherapy.